๐ข ๐๐จ๐ฆ๐ง ๐๐ก: Novo Nordisk Raises 2026 Outlook on Stronger GLP-1 Sales Expectations - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)
๐ ๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐:โค ๐ก๐ผ๐๐ผ ๐ก๐ผ๐ฟ๐ฑ๐ถ๐๐ธ raised its full-year ๐ฎ๐ฌ๐ฎ๐ฒ adjusted guidance.โค Higher outlook reflects stronger expected ๐๐๐ฃ-๐ญ product sales.โค Adjusted sales guidance improved to ๐ฌ% ๐๐ผ -๐ฒ% at CER.โค Previous adjusted sales outlook was -๐ฐ% ๐๐ผ -๐ญ๐ฎ% at CER.โค Adjusted operating profit guidance improved to ๐ฌ% ๐๐ผ -๐ฒ% at CER.โค ๐ค๐ฎ adjusted sales reached ๐๐๐ ๐ณ๐ด,๐ฐ๐ด๐ด ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป, up ๐ณ% at CER.โค ๐ค๐ฎ adjusted operating profit totaled ๐๐๐ ๐ฏ๐ฏ,๐ฏ๐ด๐ต ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป, up ๐ญ๐ญ% at CER.โค Results exclude one-time impacts from the U.S. ๐ฏ๐ฐ๐ฌ๐ ๐๐ฟ๐๐ด ๐ฃ๐ฟ๐ถ๐ฐ๐ถ๐ป๐ด ๐ฃ๐ฟ๐ผ๐ด๐ฟ๐ฎ๐บ.โค ๐ค๐ฎ included ๐๐๐ ๐ฒ.๐ฏ ๐ฏ๐ถ๐น๐น๐ถ๐ผ๐ป in non-cash impairment charges.๐ ๐ช๐ต๐ ๐ง๐ต๐ถ๐ ๐ ๐ฎ๐๐๐ฒ๐ฟ๐:โค Improved guidance signals stronger-than-expected demand for ๐๐๐ฃ-๐ญ therapies.โค Higher outlook may strengthen investor confidence in Novo Nordisk's earnings trajectory.โค Excluding one-time items provides a clearer view of underlying operating performance.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments